Investor Presentaiton
Darovasertib + Crizotinib First-Line MUM Combo Efficacy
Examples of cPRS with Significant Tumor Shrinkage in First-Line MUM Patients
First-Line MUM Patient
40+ year old HLA-A2 positive patient with Class 1A diagnosis
metastasized after ~6 years
Diffuse disease in liver and pelvis with elevated LDH of 800
normalized within one month of treatment
Large tumors (SLD = 210 mm) reduced by 49%
On treatment for over 15 months
Baseline
12 months
Many lesions distorting and replacing the
liver
Marked improvement
across all lesions
15
IDEAYA Data as of 03/08/2023 (based on preliminary analysis of unlocked database); tumor lesion reductions by investigator review
First-Line MUM Patient
•
•
40+ year old HLA-A2 negative patient with Class 1A diagnosis
metastasized in ~1 year
Many liver lesions with maximal target lesion reduction of 65%
Ongoing response
Remains on treatment at 10 months
Baseline
8 months
Many liver lesions & target lesion
Marked improvement
across all lesions
IDEAVA
BIOSCIENCESView entire presentation